NATALIE KOSTER: Open Payments
NPI 1619733532 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$876 in 38 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $188 · 2025 $876
Food & beverage: $876
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $200 |
| AstraZeneca Pharmaceuticals LP | 5 | $156 |
| Lilly USA, LLC | 2 | $124 |
| PFIZER INC. | 3 | $73 |
| SANOFI PASTEUR INC. | 2 | $59 |
| Boston Scientific Corporation | 1 | $43 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| BridgeBio Pharma, Inc. | 1 | $28 |
| SHIELD THERAPEUTICS INC | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
Products named: KISUNLA, Ozempic, FARXIGA, PREVNAR 20, Wegovy, APOLLO ESG System, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Attruby.
Industry payments across TX — which companies pay providers there.
